Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC.
about
Role of Akt signaling in resistance to DNA-targeted therapyAddressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapiesUp-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J.Enhancement of TRAIL-induced apoptosis by 5-fluorouracil requires activating Bax and p53 pathways in TRAIL-resistant lung cancers.Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapyRetaining MKP1 expression and attenuating JNK-mediated apoptosis by RIP1 for cisplatin resistance through miR-940 inhibitionInherited variation in the ATP-binding cassette transporter ABCB1 and survival after chemotherapy for stage III-IV lung cancerMolecular imaging in therapeutic efficacy assessment of targeted therapy for nonsmall cell lung cancerGenistein enhances the effect of cisplatin on the inhibition of non-small cell lung cancer A549 cell growth in vitro and in vivo.A signaling pathway consisting of miR-551b, catalase and MUC1 contributes to acquired apoptosis resistance and chemoresistance.RAGE genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLCAssociation of PSMA4 polymorphisms with lung cancer susceptibility and response to cisplatin-based chemotherapy in a Chinese Han population.The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1) expressionSynergistic anticancer effect of cisplatin and Chal-24 combination through IAP and c-FLIPL degradation, Ripoptosome formation and autophagy-mediated apoptosis.Efficacy and safety of docetaxel for advanced non-small-cell lung cancer: a meta-analysis of Phase III randomized controlled trials.DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell linesEnhanced expression of stem cell markers and drug resistance in sphere-forming non-small cell lung cancer cells.Repurposing Cationic Amphiphilic Antihistamines for Cancer TreatmentPIWIL2 promotes progression of non-small cell lung cancer by inducing CDK2 and Cyclin A expressionTumour suppressor genes in chemotherapeutic drug response.Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy.A measles virus selectively blind to signaling lymphocytic activation molecule shows anti-tumor activity against lung cancer cells.Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum.MicroRNA-7 Compromises p53 Protein-dependent Apoptosis by Controlling the Expression of the Chromatin Remodeling Factor SMARCD1.CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential.Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrestSignificance of IASLC/ATS/ERS classification for early-stage lung adenocarcinoma patients in predicting benefit from adjuvant chemotherapySubamolide a induces mitotic catastrophe accompanied by apoptosis in human lung cancer cellsWeekly intravenous nanoparticle albumin-bound paclitaxel for elderly patients with stage IV non-small-cell lung cancer: a series of 20 cases.A preclinical evaluation of antimycin a as a potential antilung cancer stem cell agent.Differential effects of MTSS1 on invasion and proliferation in subtypes of non-small cell lung cancer cellsCisplatin treatment increases stemness through upregulation of hypoxia-inducible factors by interleukin-6 in non-small cell lung cancer.Anticancer Activity of Novel Daphnane Diterpenoids from Daphne genkwa through Cell-Cycle Arrest and Suppression of Akt/STAT/Src Signalings in Human Lung Cancer Cells.A2780 human ovarian cancer cells with acquired paclitaxel resistance display cancer stem cell properties.Expression of LRIG1 is Associated With Good Prognosis for Human Non-small Cell Lung Cancer.An Acetamide Derivative as a Camptothecin Sensitizer for Human Non-Small-Cell Lung Cancer Cells through Increased Oxidative Stress and JNK Activation.Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway.Role of gambogic acid and NaI131 in A549/DDP cells.Receptor-interacting protein 1 increases chemoresistance by maintaining inhibitor of apoptosis protein levels and reducing reactive oxygen species through a microRNA-146a-mediated catalase pathway.Overexpression of TNKS1BP1 in lung cancers and its involvement in homologous recombination pathway of DNA double-strand breaks.
P2860
Q28066950-0C2A122B-134F-4B03-A8EF-5D75B127AB1CQ28074716-E86A17F2-25E1-43D6-A84A-B49CE521DA40Q32182056-F25AB422-D116-4A54-8F68-821EBFCEA5D6Q33566824-BACA4635-32B1-450F-A5B8-FE7F2200CFAFQ33572407-B9EC7116-A3EE-4E36-9A56-8F7F065276EAQ33576820-7894C9D9-2AFB-4B55-BD94-5760E8CDD423Q34050097-D057DB87-BD9E-4E9E-8956-F146121CA971Q34243500-A64D2B42-185D-4A58-BB9F-129742CB5328Q34427365-BC81E44F-095A-45A1-887F-A24C94AA640CQ34434902-491949D9-D35D-4D3C-8808-2FBD0874B211Q34446751-15F57170-0377-46FA-9F54-A7470DB5E7FAQ34465945-AABE6939-8B64-49C8-B2F9-FDF3E3469393Q35025421-3B89F3F4-93AE-4C2A-91DE-1D9F3EDDCE27Q35176405-F3B90278-6EA2-46E5-BC9E-4D8CF57B53EFQ35766183-B0C2EF9D-E022-47C3-9C06-C14BC4B9BE82Q35768464-44A86E6C-4433-4C6F-B5C9-00CE27D754CEQ35918956-B54B9FD3-6C2C-404D-8039-A7C66B20BCD6Q36059021-54406FD4-22B5-48FA-8556-B8D84D2EF4EFQ36063180-C697C5A0-03F8-4A1D-BB00-30984EA08126Q36083098-6E7002D0-248A-4FAA-9A58-AFBD3C43D3CAQ36213062-D622A437-6B0D-4013-A619-DDB4715E7E62Q36413058-B4BAD070-FCF4-453D-A2FB-62BE3E402ED8Q36457582-350C4C19-4A0B-44EB-B8D0-D3EE30A9691EQ36489308-DAEEDD2C-E2AB-4076-97C5-4079482F0FB2Q36583985-39DB982A-79DA-4F2E-BBA5-7A24B7307CC7Q36586535-4057D734-FDFB-4630-BB72-B730FF523942Q36656090-C7C3946C-A3FA-4657-9EBA-AEDA3A8D9F0AQ36679052-3EBB2BCE-2779-4C08-8F18-885A1C2F7D82Q36680050-04E129D9-5074-4217-885D-BA4C9760D3F9Q36955985-E71D4AF9-5572-435E-9193-78CBBA85D7BEQ37107726-ECCBB8E8-D610-4634-9D24-511C3EA8EEFDQ37142438-A81C2FD7-1DD0-4A0D-A34F-6DE666F5195BQ37145412-14E475A3-69C8-41B8-9699-450D99F6186BQ37269467-64FBCA47-D29A-44A0-ABA3-D2BFA0A39056Q37328598-326ABBA4-6DD5-460C-8118-5C169226D95EQ37397101-B9CB0DA7-EF87-4EEE-8747-1A11376679FEQ37476178-4FF365AD-D164-4D65-B477-E3F5F059DD68Q37594133-C67B73D2-0DC4-4AD5-837F-D9FB373E0711Q37608457-79C4CEE9-F04B-44BC-856B-A5DC408EB047Q37648119-29849AF2-8666-4F08-A8C1-FE67F07E4E57
P2860
Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC.
@en
Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC.
@nl
type
label
Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC.
@en
Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC.
@nl
prefLabel
Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC.
@en
Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC.
@nl
P1433
P1476
Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC.
@en
P2093
Alex Chang
P356
10.1016/J.LUNGCAN.2010.08.022
P577
2010-10-16T00:00:00Z